DOM-CIPROFLOXACIN TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

şimdi satın al

Ürün özellikleri Ürün özellikleri (SPC)
10-09-2019

Aktif bileşen:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)

Mevcut itibaren:

DOMINION PHARMACAL

ATC kodu:

J01MA02

INN (International Adı):

CIPROFLOXACIN

Doz:

100MG

Farmasötik formu:

TABLET

Kompozisyon:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 100MG

Uygulama yolu:

ORAL

Paketteki üniteler:

100

Reçete türü:

Prescription

Terapötik alanı:

QUINOLONES

Ürün özeti:

Active ingredient group (AIG) number: 0123207005; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2004-03-24

Ürün özellikleri

                                PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
DOM-CIPROFLOXACIN
(Ciprofloxacin Hydrochloride Tablets, USP)
100 mg, 250 mg, 500 mg and 750 mg
ANTIBACTERIAL AGENT
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100,
Montréal, Quebec
H4P 2T4 DATE OF REVISION: SEPTEMBER 10, 2019
SUBMISSION CONTROL NO.: 229111
_Dom-CIPROFLOXACIN Product Monograph _
_Page 2 of 49_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
6
WARNINGS AND PRECAUTIONS
............................................................................................
6
ADVERSE REACTIONS
............................................................................................................
11
DRUG INTERACTIONS
............................................................................................................
14
DOSAGE AND ADMINISTRATION
........................................................................................
19
OVERDOSAGE
...........................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
21
STORAGE AND STABILITY
....................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 23
PART II: SCIENTIFIC INFORMATION
..................................................................................
25
PHARMACEUTICAL INFORMATION
..........................................................................
                                
                                Belgenin tamamını okuyun
                                
                            

Diğer dillerdeki belgeler

Ürün özellikleri Ürün özellikleri Fransızca 10-09-2019

Bu ürünle ilgili arama uyarıları

Belge geçmişini görüntüleyin